EGFR and lung carcinoma: In July 2013, the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology (CAP/IASLC/AMP) released guidelines recommending that EGFR mutation testing be used to guide the choice of EGFR inhibitor treatment [7].